Inhaled Steroids Modulate Extracellular Matrix Composition in Bronchial Biopsies of COPD Patients: A Randomized, Controlled Trial
Open Access
- 7 May 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (5) , e63430
Abstract
Smoking and inflammation contribute to the pathogenesis of chronic obstructive pulmonary disease (COPD), which involves changes in extracellular matrix. This is thought to contribute to airway remodeling and airflow obstruction. We have previously observed that long-term treatment with inhaled corticosteroids can not only reduce bronchial inflammation, but can also attenuate lung function decline in moderate-severe COPD. We hypothesized that inhaled corticosteroids and current smoking modulate bronchial extracellular matrix components in COPD. To compare major extracellular matrix components (elastic fibers; proteoglycans [versican, decorin]; collagens type I and III) in bronchial biopsies 1) after 30-months inhaled steroids treatment or placebo; and 2) between current and ex-smokers with COPD. We included 64 moderate-severe, steroid-naive COPD patients (24/40 (ex)-smokers, 62±7 years, 46 (31–54) packyears, post-bronchodilator forced expiratory volume in one second (FEV1) 62±9% predicted) at baseline in this randomized, controlled trial. 19 and 13 patients received 30-months treatment with fluticasone or placebo, respectively. Bronchial biopsies collected at baseline and after 30 months were studied using (immuno)histochemistry to evaluate extracellular matrix content. Percentage and density of stained area were calculated by digital image analysis. 30-Months inhaled steroids increased the percentage stained area of versican (9.6% [CI 0.9 to 18.3%]; p = 0.03) and collagen III (20.6% [CI 3.8 to 37.4%]; p = 0.02) compared to placebo. Increased collagen I staining density correlated with increased post-bronchodilator FEV1 after inhaled steroids treatment (Rs = 0.45, p = 0.04). There were no differences between smokers and ex-smokers with COPD in percentages and densities for all extracellular matrix proteins. These data show that long-term inhaled corticosteroids treatment partially changes the composition of extracellular matrix in moderate-severe COPD. This is associated with increased lung function, suggesting that long-term inhaled steroids modulate airway remodeling thereby potentially preventing airway collapse in COPD. Smoking status is not associated with bronchial extracellular matrix proteins. ClinicalTrials.gov NCT00158847Keywords
This publication has 36 references indexed in Scilit:
- Smoking status and anti-inflammatory macrophages in bronchoalveolar lavage and induced sputum in COPDRespiratory Research, 2011
- New insights into the immunology of chronic obstructive pulmonary diseaseThe Lancet, 2011
- Differential Expression of Tissue Repair Genes in the Pathogenesis of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Multidrug resistance-associated protein-1 (MRP1) genetic variants, MRP1 protein levels and severity of COPDRespiratory Research, 2010
- Altered fibroblast proteoglycan production in COPDRespiratory Research, 2010
- Smad gene expression in pulmonary fibroblasts: indications for defective ECM repair in COPDRespiratory Research, 2008
- Extracellular matrix mechanics in lung parenchymal diseasesRespiratory Physiology & Neurobiology, 2008
- Changes in elastin, elastin binding protein and versican in alveoli in chronic obstructive pulmonary diseaseRespiratory Research, 2008
- Changes in elastic fibres in the small airways and alveoli in COPDEuropean Respiratory Journal, 2008
- Relation between duration of smoking cessation and bronchial inflammation in COPDThorax, 2006